<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439034</url>
  </required_header>
  <id_info>
    <org_study_id>KETOCOL-1304</org_study_id>
    <nct_id>NCT02439034</nct_id>
  </id_info>
  <brief_title>Paracetamol With or Without Ketoprofen in the Management of Pain for Patients Receiving Brachytherapy (KETOCOL-1304)</brief_title>
  <acronym>KETOCOL-1304</acronym>
  <official_title>Paracetamol With or Without Ketoprofen in the Management of Pain During Hospitalisation and at Home for Patients Receiving Brachytherapy: Phase-2 Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SANTELYS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The results of the study will permit to set up a standardized and validated procedure of pain
      management authorizing medical and paramedical staff of brachytherapy department to handle
      pain and in this way to improve the quality of life of the patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Selection criteria validation

        -  Patient information and collection of a signed informed consent

        -  Randomization

        -  Completion of HADS questionnaire

        -  Day 1 = Begin of analgesic treatment / brachytherapy

        -  T-30= 30 minutes before the operative procedure, IV administration of the analgesic
           treatment (Arm A or B) by the anesthetist

        -  T0= end of the operative procedure under general anesthesia

        -  T4, T8, and T12 = 4, 8 and 12 hours after T0: evaluation of pain level. If pain level ≥
           4:

             1. paracetamol-codeine (Arms A and B) and continuation of ketoprofen (Arm B). Then, if
                persistence of pain :

             2. paracetamol and morphine (Arms A and B)

        -  Day 2 to Day 30: At home or during hospital stay:

      Pain assessment twice a day by the patient until absence of pain during 2 consecutive days

        -  Day 3 and Day 15: Pain assessment or phone interview by the algologist of the
           investigation center ; completion of a HADS questionnaire on Day 3

        -  Day 30= End of study: Pain assessment by the algologist of the investigation center and
           HADS questionnaire

      In any case, pain assessment must be done until absence of pain during 2 consecutive days
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of immediate post-operative pain</measure>
    <time_frame>Day 1</time_frame>
    <description>Immediate post-operative pain will be assessed on a scale from 0 to 10. Experimental treatment will be considered as a success if the level of pain is &lt; 4, 4 hours after the surgical operation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of pain linked to the operative procedure during brachytherapy and at home</measure>
    <time_frame>Day 1 (8, 12 hours), Days 3, 15 and 30</time_frame>
    <description>Assessment of the pain level at 8, 12 hours after the operative procedure, then twice a day during hospital stay or at home until the absence of pain during 2 consecutive days. This level will also be measured at days 3, 15 and 30 at hospital or during a phone interview (Days 3 and 15) and by the algologist of the investigation center on Day 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of the analgesic treatment</measure>
    <time_frame>30 days</time_frame>
    <description>assessment based on NCI-CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of anxiety before, during and after brachytherapy by completing the HADS questionnaire</measure>
    <time_frame>inclusion, Days 3 and 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Uterine Cervical Cancer</condition>
  <condition>Upper Aerodigestive Tract Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paracetamol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paracetamol + Ketoprofen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>PARACETAMOL B BRAUN</other_name>
    <other_name>PARACETAMOL CODEINE ARROW</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoprofen</intervention_name>
    <description>Ketoprofen* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>BI PROFENID LP</other_name>
    <other_name>PROFENID</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with a uterine cervical cancer or an upper aero-digestive tract cancer

          -  Age ≥ 18 years and ≤ 75 years

          -  Patient who are eligible for brachytherapy treatment associated with or without
             hospital stay

          -  With operative procedure under general anesthesia to set up the material needed for
             brachytherapy

          -  Performance status ≤ 2

          -  Creatinine Clearance ≥ 60 ml/min using Cockcroft equation

          -  No coagulation disorder or anticoagulation therapy at curative dose

          -  Registered with a social security system

          -  Patient having dated and signed an informed consent form before initiation of any
             study procedures

        Exclusion Criteria:

          -  Respiratory pathology (SpO2&lt; 70 %)

          -  Severe undernutrition

          -  Previous hypersensitivity reactions such as bronchospasm, asthma, rhinitis, hives or
             other allergic reaction to ketoprofen, to acetylsalicylic acid, or other NSAIDs

          -  Previous hemorrhage or gastrointestinal perforation during a previous treatment with
             NSAID

          -  Gastrointestinal hemorrhage , cerebrovascular hemorrhage or other evolutive hemorrhage

          -  Evolutive peptic ulcer, previous peptic ulcer or recurring hemorrhage (2 or more
             distinct episodes of hemorrhage or ulcer objectified)

          -  Liver insufficiency

          -  Severe renal insufficiency

          -  Severe heart failure

          -  Treatment with another NSAID, including selective cyclooxygenase-2 inhibitors

          -  Intolerance or hypersensitivity to one of the treatments or excipients

          -  Inability to swallow

          -  Pregnant or breastfeeding woman

          -  Patient under tutorship or guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danièle LEFEBVRE-KUNTZ, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathalie LEROUX, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danièle LEFEBVRE-KUNTZ, MD</last_name>
    <phone>+33 3 20 29 59 89</phone>
    <email>d-lefebvre@o-lambret.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie LEROUX-BROMBERG, MD</last_name>
    <phone>+33 3 20 29 59 89</phone>
    <email>n-leroux@o-lambret.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danièle Lefebvre-Kuntz, MD</last_name>
      <phone>+33 3 20 29 59 89</phone>
      <email>d-lefebvre@o-lambret.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie Leroux-Bromberg, MD</last_name>
      <phone>+33 3 20 29 59 89</phone>
      <email>n-leroux@o-lambret.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Danièle Lefebvre-Kuntz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie Leroux-Bromberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abesse Ahmeidi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnès Hamdani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eliane Boufflers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Lartigau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Coche-Dequeant, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abel Cordoba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Maillard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier Delbrouck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain management</keyword>
  <keyword>brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ketoprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

